相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing
Li Li et al.
TRANSLATIONAL ONCOLOGY (2021)
A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action
Xuesai Zhang et al.
MOLECULAR IMMUNOLOGY (2020)
The BiTE (Bispecific T-Cell engager) platform: development and future potential of a targeted immuno-oncology therapy across Tumor Types
Hermann Einsele et al.
CANCER (2020)
Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models
Regina Padmanabhan et al.
CANCERS (2020)
Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy
Shuyu Huang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Revisiting the PD-1 pathway
Nikolaos Patsoukis et al.
SCIENCE ADVANCES (2020)
Targeting Programmed Cell Death-1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
Anastasia Constantinidou et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review
Noam Ponde et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Takahiro Kamada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Application of PD-1 Blockade in Cancer Immunotherapy
Xiaomo Wu et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2019)
Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy
Deepak Mittal et al.
ONCOIMMUNOLOGY (2019)
CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Hreinn Benonisson et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig
Philip D. Bardwell et al.
PROTEIN & CELL (2018)
Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN gamma secretion
Bharat K. R. Chaganty et al.
CANCER LETTERS (2018)
Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects
Mariana Brandao et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
Sara A. Hurvitz et al.
LANCET ONCOLOGY (2018)
Bispecific antibodies: design, therapy, perspectives
Sergey E. Sedykh et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
Alberto Carretero-González et al.
Oncotarget (2018)
A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
Iris Koopmans et al.
ONCOIMMUNOLOGY (2018)
Cancer Cell-intrinsic PD-1 and implications in Combinatorial immunotherapy
Han Yao et al.
FRONTIERS IN IMMUNOLOGY (2018)
The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies
Corinne A. Levingston et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
The making of bispecific antibodies
Ulrich Brinkmann et al.
MABS (2017)
EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release
Koung Jin Suh et al.
ONCOTARGET (2017)
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Takuro Noguchi et al.
CANCER IMMUNOLOGY RESEARCH (2017)
PD-1/PD-L1 Pathway in Breast Cancer
Florian Schuetz et al.
ONCOLOGY RESEARCH AND TREATMENT (2017)
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
Andres Lopez-Albaitero et al.
ONCOIMMUNOLOGY (2017)
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
Shengnan Yu et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
PD-1 and PD-L1 antibodies in cancer: current status and future directions
Arjun Vasant Balar et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Cancer immunotherapies targeting the PD-1 signaling pathway
Yoshiko Iwai et al.
JOURNAL OF BIOMEDICAL SCIENCE (2017)
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing
Ji Li et al.
CANCER CELL (2017)
Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+breast cancer
Debora de Melo Gagliato et al.
ONCOTARGET (2016)
The PD1:PD-L1/2 Pathway from Discovery to Clinical implementation
Kankana Bardhan et al.
FRONTIERS IN IMMUNOLOGY (2016)
Bispecific antibodies and their applications
Gaowei Fan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Programmed Death-1 Controls T Cell Survival by Regulating Oxidative Metabolism
Victor Tkachev et al.
JOURNAL OF IMMUNOLOGY (2015)
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Kim C. Ohaegbulam et al.
TRENDS IN MOLECULAR MEDICINE (2015)
PD-1 and PD-L1 antibodies for melanoma
Katy K. Tsai et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
Changyu Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models
Yoriko Yamashita-Kashima et al.
CLINICAL CANCER RESEARCH (2011)
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity
Jianying Dong et al.
MABS (2011)
Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene
Nadia Harbeck et al.
BREAST CARE (2010)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Programmed death-1 concentration at the immunologicial synapse is determined by ligand affinity and availability
Tsvetelina Pentcheva-Hoang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
R Nahta et al.
CANCER RESEARCH (2004)
Role of HER2/neu in tumor progession and therapy
S Ménard et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2004)
分享论文
